Cancer Moonshot Resource Center
Free access to research, data, analyses and other resources
In his final State of the Union address, US President Barack Obama put Vice President Joseph Biden in charge of a new national effort to end cancer as we know it: the Cancer Moonshot. The goal: "To make a decade worth of advances in cancer prevention, diagnosis and treatment in five years." It's a broad-reaching, collaborative effort involving cancer researchers, healthcare professionals, patients, advocates and others with innovative ideas to contribute.
To support cancer research, Elsevier is providing free access to data, metrics, video-interviews and other resources to support research and other activities critical to this initiative. We hope researchers, healthcare providers, funders and government agencies in the US and beyond will find these resources helpful. The site will be updated as new data becomes available.
Updated on 20 November 2018
Cancer Essentials is a bi-monthly collection that provides current content on timely topics at the forefront of cancer research and oncology. Its curated by the editors of Trends in Cancer (Cell Press Reviews) and Elsevier's reference books on cancer. The content follows a progressive narrative to guide logical, easy reading.
- DNA Repair (June 2018): In this inaugural volume, we invite you to learn more about the many aspects of DNA Repair, from experimental tools and methods, to pathways and signaling, genome instability, new drugs and clinical translation.
- Immunotherapy (August 2018): This issue assembles major reviews on cancer immunotherapy, providing an important update to a field now recognized as a critical prime mover in future combination treatments to eradicate deadly cancers.
- Stem cells (November 2018): Cancer stem cells, also referred to as tumor initiating cells or tumor propagating cells, are certainly a barrier to progress. How do we target them for an achievable cure?
Lancet Oncology report sets out how to accelerate cancer research and care
A fundamental shift in how cancer research is conducted and how cancer care is delivered in the United States is required in order to deliver on the US Cancer Moonshot initiative, according to a major new report published October 31 in The Lancet Oncology journal.
Future research priorities in the USA: a Lancet Oncology Commission presents a detailed roadmap, including a focus on prevention, a new model for drug discovery and development, a vast expansion of patient access to clinical trials, and an emphasis on targeted interventions to improve cancer care for underserved groups, specifically children, cancer survivors and minority groups. The report emphasizes the importance of addressing health disparities in all recommendations.
Authored by over 50 leading oncologists in US, the report sets out 13 key priority areas, each with measurable goals, to focus the $2 billion of funding released to the National Cancer Institute as part of the 21st Century Cures Act. It highlights how technological advances, including understanding and mapping pre-cancer biology and the rapid adoption of big data, as well as new collaborations across industry, patient groups, academia, government and clinical practice will be critical to advancing research, and ultimately improving patient care.
The report was launched on November 1 in Washington, DC, and will be presented November 3 at the United Nations Association of New York Humanitarian Awards, where former Vice President Joe Biden is being honored for his work on improving cancer outcomes as part of the US Cancer Moonshot Initiative.
Joe Biden recognizes the Lancet Oncology Commission and Elsevier for their contributions to cancer research
Former VP Joe Biden addressed a national gathering at the UN November 3 that brought together cancer experts, policymakers, diplomats, UN supporters, and leaders of academia and business. He was there with Elsevier Chairman Youngsuk “YS” Chi to accept Humanitarian of the Year awards from the United Nations Association of New York (UNA-NY). Biden was recognized for his efforts in leading the Cancer Moonshot initiative, which has resulted in new programs and multidisciplinary collaborations to improve cancer research and care, while Chi was recognized for Elsevier’s support for the initiative. Read more.
New cancer research benchmark report
With this report — Cancer Research: Current Trends & Future Directions — Elsevier aims to benchmark and map out the global landscape of cancer research to provide helpful new insights.
We consider this report to be a "pre-print" version and invite you to provide comment and feedback.
The initiative to speed up cancer research, currently called the "Cancer Moonshot," is administered through the White House. After the incoming administration develops its priorities for its support for the initiative, we are looking forward to continuing to produce additional installments of the benchmark report. The nature and number of installments is not set and will be informed by input from the community and an advisory board. We anticipate four to six topic-specific installments plus an analytical summary. Our hope is to release the full report by the end of 2017.
The report is being developed with Elsevier’s Research Intelligence products and services; bibliometric data comes from the Scopus database, which is approaching 1 million peer-reviewed publications and scientific proceedings on cancer research produced in the past decade.
Part 1: Mapping out cancer research landscape globally 2011-2015
This first installment of the Elsevier benchmark report presents an overarching view of emerging trends, many of which will be examined in greater detail in subsequent chapters.
Here are some highlights of the findings:
From the White House
White House hosts Cancer Moonshot event and working discussion
Washington, DC, October 17, 2016 — Vice President Joe Biden hosted a private event at the White House to discuss the Report of the Cancer Moonshot Task Force released that morning and chart the progress of the initiative, led by Executive Director Greg Simon. Biden said the effort’s funding cannot be centered on the work of individual researchers but on partnerships that will help realize the goals of the Moonshot. He called on participants to help transform it into a true "social movement." The partnerships announced at the meeting included both business and philanthropic commitments to support research and data-sharing.
As a partner in the Moonshot, Elsevier was represented by Dr. Lily Khidr, a cancer researcher who has transitioned into publishing. After the meeting, she remarked on impressive roster of attendees, including FDA Commission Dr. Rob Califf, NIH Director Dr. Francis Collins and Acting NCI Director Dr. Douglas Lowy, then added:
Truly the most important person in the room was sitting right next to me. Her name was Scarlett James, and she was the only child in the room: a T-cell lymphoma survivor at the age of 9. Suffice to say, it put everything into sharp perspective. The patient was truly at the center of the conversation.
- Read more about this meeting and the new partnerships.
- Read the Report of the Cancer Moonshot Task Force and related content.
- Watch a video of the press briefing below or read the transcript.
In the spotlight
VP Joe Biden talks about the Cancer Moonshot with Stephen Colbert
On the Late Show with Stephen Colbert December 7, 2016, Vice President Joe Biden talked about the bill that will fund the Cancer Moonshot initiative. It was named for his late son Beau Biden, who died from brain cancer at the age of 46. He told Colbert:
Shortly after Beau died, I asked myself, ‘What would Beau do if he were here?’ And I devoted my life to doing what I thought Beau would do. … I know that if it were reversed, Beau would be spending his time doing all in his power to try to bring together these great minds in the cancer research field all around the world to focus, and have a greater sense of urgency, on what can be done in the next five years that would ordinary take 10.
Biden also stressed the importance of sharing data in the medical community, pointing out that we have tools today that didn't exist in decades past:
There have been hundreds of thousands … of cancer genomes that have been sequenced – all this data. And one of the things we found out is that, if we’re prepared to share this data, which the culture of medicine isn’t prepare to do yet … we can find answers.
Watch the interview here:
Access to research
These papers relate to the recommendations put forward by the Cancer Moonshot’s Blue Ribbon Panel. They have been carefully selected by Elsevier’s oncology journal teams. We have made them freely available.
- Adrian Towse, Louis Garrison: Value assessment in precision cancer medicine, Research article, Journal of Cancer Policy (September 2016)
- Ji Luo: CRISPR/Cas9: From Genome Engineering to Cancer Drug Discovery, review paper, Trends in Cancer (June 2016)
- Rebecca A. Burrell, Charles Swanton: Re-Evaluating Clonal Dominance in Cancer Evolution, review paper, Trends in Cancer (May 2016)
- Erika Langsfeld, Laimonis A. Laimins: Human Pappilomaviruses: Research Priorities for the next Decade, opinion article, Trends in Cancer (May 2016)
- Douglas B. Johnson et al, Acquired BRAF inhibitor resistance: A multi-centre meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms, Research paper, European Journal of Cancer (December 2015)
- Barbara C. Worst et al, Next generation personalised medicine for high-risk paediatric cancer patients – The INFORM pilot study, Research paper, European Journal of Cancer (September 2016)
- Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation, Research paper, Journal of Thoracic Oncology (June 2015) – open archive
Editorials and other articles
- Targeted Therapy for Brain Metastases in EGFR-Mutated and ALK-Rearranged Non-Small-Cell Lung Cancer, Review paper, Journal of Thoracic Oncology (September 2015) – open archive
- Alexander M.M. Eggermont, Guido Kroemer, Laurence Zitvogel: Immunotherapy and the concept of a clinical cure, Position Paper, European Journal of Cancer (September 2013)
- Programmed Death-Ligand 1 Immunohistochemistry in Lung Cancer: In what state is this art? Review paper, Journal of Thoracic Oncology (July 2015) – open archive
- Launching a plan for the Cancer Moonshot, Editorial, The Lancet (September 2016)
- Edith Mitchell, M.D.: Moonshot Toward a Cure for Cancer, President’s message, Journal of the National Medical Association (September 2016)
- Anand Shah, Kelsey I Ricci, Jason A Efstathiou: Beyond a moonshot: insurance coverage for proton therapy, Comment, The Lancet Oncology (May 2016)
- C Marjorie Aelion, The US Cancer Moonshot initiative, Correspondence, The Lancet Oncology (May 2016)
- How text mining is changing the way we tackle chronic disease (Elsevier Connect, Nov. 9, 2017)
- National Cancer Institute – Cancer Moonshot
- White House Cancer Moonshot Task Force
- The Lancet Oncology: Cancer Control Hub
- At Cancer Moonshot Summit, Elsevier presents plans for benchmark report (Elsevier Connect, July 7, 2016)
- Elsevier to Develop First-Ever Benchmark Report on US Cancer Research Landscape (Elsevier press release, June 29, 2016)
- Helping the NIH use informatics to combat cancer (Elsevier Connect)
- Innovations In Science: Pursuing Another Giant Leap For Mankind; Olivier Dumon writes about how collaboration, technology and economics will play vital roles in future cancer research (Huffington Post, June 29, 2016)